The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
Alphabet spin-out Isomorphic Labs is in preliminary discussions to raise external capital at a valuation of at least $40 billion, according to reporting from Bloomberg.
Roche has entered a research collaboration with Chinese startup Defand Therapeutics to discover and develop molecular glue drugs for cancer and immune diseases.
Two companion papers in Science and Cell report using synthetic DNA recording platforms, including DNA Typewriter, to reconstruct cell lineage trees from a fertilized egg through late organogenesis in mice.
In the Phase 3 EXCALIBER-RRMM trial, patients receiving the oral cereblon E3 ligase modulator Zenbexus (iberdomide) combined with standard therapies reached a median progression-free survival of 42 months, compared to 20 months for standard DVd therapy.
The Advanced Research Projects Agency for Health has funded three teams under its BioStabilization Systems program, committing up to $87 million over four years to eliminate cold-chain refrigeration for living cell products.
The computational drug design startup spun out of Google DeepMind is negotiating a fresh financing round that could value the company between $40 billion and $50 billion.
Viatris will pay $36.50 per share to purchase the pain-management specialist, funding the transaction primarily from excess cash.
Regulators cleared the oral small-molecule HER2 kinase inhibitor for first-line maintenance in advanced HER2-positive breast cancer in combination with antibody therapies.
Endeavor BioMedicines announced that its oral Hedgehog inhibitor, taladegib, met the primary endpoint in a Phase 2b trial of 213 patients with idiopathic pulmonary fibrosis.
The US Food and Drug Administration placed a clinical hold on American sites testing evenamide, Newron Pharmaceuticals' oral voltage-gated sodium channel blocker for schizophrenia, after four patient deaths occurred during the late-stage study.
Topline Phase 2 data from 220 patients with obesity and Type 2 diabetes showed petrelintide drove up to 9.2% weight loss at 28 weeks compared to 2% for placebo, matching competitive amylin-agonist benchmarks.
Biohaven out-licensed Asian rights to three extracellular protein degraders to Ono Pharmaceutical for $80 million upfront, with an additional $20 million milestone payment and a 20% cut of regional sales.
Argenx said its anti-CD122 monoclonal antibody, FB102, significantly improved gut tissue architecture compared to placebo in a 126-patient Phase 2 trial of adults undergoing an oral gluten challenge.
Engineers developed an end-to-end deep neural network that restores low-light fluorescence microscopy images and strips out-of-focus background haze using only a single frame.
Researchers introduced latent causal diffusion (LCD), a generative diffusion framework designed to model single-cell perturbation responses while accounting for measurement noise.
Researchers have released Tangermeme, an optimized computational package designed to interpret the complex regulatory logic learned by genomic deep-learning models.
A global competition named Bits to Binders evaluated 12,000 AI-designed 80-amino acid mini-proteins as the targeting heads for CAR T-cell therapies against human CD20.
Researchers developed PK-MUSE, a computational model that marries traditional two-compartment physiological equations with neural networks to predict human drug concentration over time directly from chemical structure.
Researchers built SpatialOmicsLab, an evaluation suite combining 113 analytical tools, 63 reference datasets, and 4,614 task specifications for spatial transcriptomics, alongside an AI agent named ST-Coscientist designed to assemble and run those workflows.
Computational biologists evaluating metamorphic proteins, which switch between distinct three-dimensional folds, found that protein language models rely heavily on sequence memorization and fail to generalize to novel shape-shifting regions.
Researchers built a deep-learning model called InfluProto that evaluates the cross-species transmission risk of influenza A by framing host adaptation on a continuous spectrum rather than as rigid categories.
Researchers built an all-atom computational design method that controls the composition of attached sugars, known as N-linked glycans, by shaping the surrounding protein backbone.
Researchers built REFinder, a pipeline that uses a DNA language model called REBEAN to label raw sequencing reads by enzyme class and assemble only sequences with putative catalytic signatures.
Researchers developed VINTER, a generative vision-language model trained on 1.45 million histology-caption pairs that jointly processes tissue morphology, local gene counts, and spatial neighborhoods.
Researchers built Hyper Screening X, a generative flow network that bakes reaction rules directly into design algorithms to search an 11-trillion make-on-demand compound library while scoring only 10 million candidates.
Researchers built an automated computational pipeline to segment and classify the ionic current blips produced as individual peptides pass through a nanopore.
Researchers replaced decades-old loop-specific nearest neighbor rules for nucleic acid folding with a single transfer matrix formulation that models the free energy of all loop types as the trace of a matrix product.
Researchers built ViabiLens, a computer vision system that couples a cell detection algorithm with a convolutional neural network to predict whether cells are alive or dead using unstained brightfield microscopy.